CytoMed Therapeutics Ltd SEC filings GDTC
CytoMed Therapeutics Ltd has 132 filings in SEC EDGAR's recent list, going back to Sep 28, 2021. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 13, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 23, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 16, 2026 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 13, 2026 | — |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 9, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Jun 30, 2026 |
| 144 | Notice of proposed sale | Aug 11, 2026 | — |
| 4/A | Filing | Jul 24, 2026 | Jul 14, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Jul 24, 2026 | — |
| 4 | Insider transaction | Jul 24, 2026 | Jul 14, 2026 |
| 6-K | Current report (foreign issuer) | Jun 23, 2026 | Jun 23, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 8, 2026 |
| 6-K | Current report (foreign issuer) | Jun 3, 2026 | Jun 3, 2026 |
| 3 | Initial insider ownership | May 26, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | May 15, 2026 | Mar 18, 2026 |
| 6-K | Current report (foreign issuer) | May 15, 2026 | May 15, 2026 |
| 144 | Notice of proposed sale | May 13, 2026 | — |
| 6-K | Current report (foreign issuer) | May 11, 2026 | May 11, 2026 |
| 6-K | Current report (foreign issuer) | Apr 14, 2026 | Apr 14, 2026 |
| 6-K | Current report (foreign issuer) | Mar 31, 2026 | Mar 31, 2026 |
| 20-F | Annual report (foreign issuer) | Mar 31, 2026 | Dec 31, 2025 |
| 144 | Notice of proposed sale | Feb 12, 2026 | — |
| 6-K | Current report (foreign issuer) | Jan 28, 2026 | Jan 28, 2026 |
| 6-K | Current report (foreign issuer) | Jan 13, 2026 | Jan 13, 2026 |
| 6-K | Current report (foreign issuer) | Dec 8, 2025 | Dec 8, 2025 |
| 6-K | Current report (foreign issuer) | Nov 18, 2025 | Nov 18, 2025 |
| 6-K | Current report (foreign issuer) | Nov 6, 2025 | Nov 6, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 29, 2025 | — |
| 6-K | Current report (foreign issuer) | Oct 22, 2025 | Oct 22, 2025 |
| 6-K | Current report (foreign issuer) | Oct 14, 2025 | Oct 14, 2025 |
| 6-K | Current report (foreign issuer) | Oct 2, 2025 | Oct 2, 2025 |
| 6-K | Current report (foreign issuer) | Sep 30, 2025 | Jun 30, 2025 |
| 144 | Notice of proposed sale | Sep 22, 2025 | — |
| 6-K | Current report (foreign issuer) | Aug 28, 2025 | Aug 28, 2025 |
| 6-K | Current report (foreign issuer) | Aug 19, 2025 | Aug 18, 2025 |
| 424B5 | Prospectus supplement | Aug 18, 2025 | — |
| 6-K | Current report (foreign issuer) | Jul 21, 2025 | Jul 21, 2025 |
| 6-K | Current report (foreign issuer) | Jul 3, 2025 | Jul 3, 2025 |
| 6-K | Current report (foreign issuer) | Jul 3, 2025 | Jul 3, 2025 |
| EFFECT | Filing | Jun 23, 2025 | — |
| 144 | Notice of proposed sale | Jun 23, 2025 | — |
| CORRESP | Letter to the SEC | Jun 20, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Jun 13, 2025 | — |
| 6-K | Current report (foreign issuer) | May 16, 2025 | May 16, 2025 |
| 6-K | Current report (foreign issuer) | Apr 28, 2025 | Apr 28, 2025 |
| 20-F | Annual report (foreign issuer) | Apr 28, 2025 | Dec 31, 2024 |
| 144 | Notice of proposed sale | Mar 24, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Mar 24, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Mar 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 4, 2025 | — |
| S-8 | Employee stock plan registration | Jan 6, 2025 | — |
| 6-K | Current report (foreign issuer) | Jan 6, 2025 | Jan 6, 2025 |
| 6-K | Current report (foreign issuer) | Dec 5, 2024 | Dec 5, 2024 |
| 6-K | Current report (foreign issuer) | Nov 20, 2024 | Nov 20, 2024 |
| 144 | Notice of proposed sale | Nov 4, 2024 | — |
| 6-K | Current report (foreign issuer) | Oct 7, 2024 | Oct 7, 2024 |
| 6-K | Current report (foreign issuer) | Oct 3, 2024 | Oct 3, 2024 |
| 6-K | Current report (foreign issuer) | Sep 30, 2024 | Sep 30, 2024 |
| 6-K/A | Filing | Jun 24, 2024 | Jun 24, 2024 |
| 6-K | Current report (foreign issuer) | Jun 20, 2024 | Jun 20, 2024 |
| 6-K | Current report (foreign issuer) | May 24, 2024 | May 24, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | May 23, 2024 | — |
| 6-K/A | Filing | Apr 25, 2024 | Apr 25, 2024 |
| 6-K | Current report (foreign issuer) | Apr 24, 2024 | Apr 24, 2024 |
| 20-F | Annual report (foreign issuer) | Apr 22, 2024 | Dec 31, 2023 |
| 6-K | Current report (foreign issuer) | Mar 18, 2024 | Mar 18, 2024 |
| 6-K | Current report (foreign issuer) | Mar 4, 2024 | Mar 4, 2024 |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
| 6-K | Current report (foreign issuer) | Jan 29, 2024 | Jan 29, 2024 |
| 6-K | Current report (foreign issuer) | Nov 17, 2023 | Jun 30, 2023 |
| 6-K | Current report (foreign issuer) | Sep 25, 2023 | Sep 25, 2023 |
| 6-K | Current report (foreign issuer) | Aug 1, 2023 | Aug 1, 2023 |
| 6-K | Current report (foreign issuer) | Jul 6, 2023 | Jul 6, 2023 |
| SC 13D | Ownership over 5% (active) | May 19, 2023 | — |
| 20-F | Annual report (foreign issuer) | May 1, 2023 | Dec 31, 2022 |
| SC 13G | Ownership over 5% (passive) | Apr 24, 2023 | — |
| SC 13D | Ownership over 5% (active) | Apr 21, 2023 | — |
| 6-K | Current report (foreign issuer) | Apr 18, 2023 | Apr 18, 2023 |
| 424B4 | Prospectus | Apr 17, 2023 | — |
| 3 | Initial insider ownership | Apr 17, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 17, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| 3 | Initial insider ownership | Apr 14, 2023 | Mar 31, 2023 |
| CERT | 8a cert | Apr 14, 2023 | — |
| SEC STAFF LETTER | Filing | Mar 31, 2023 | — |
| EFFECT | Filing | Mar 31, 2023 | — |
| CORRESP | Letter to the SEC | Mar 31, 2023 | — |
| FWP | Free writing prospectus | Mar 31, 2023 | — |
| CORRESP | Letter to the SEC | Mar 31, 2023 | — |
| CORRESP | Letter to the SEC | Mar 31, 2023 | — |
| 8-A12B | Filing | Mar 30, 2023 | — |
| CORRESP | Letter to the SEC | Mar 30, 2023 | — |
| F-1/A | Filing | Mar 30, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2023 | — |
| F-1/A | Filing | Mar 28, 2023 | — |
| F-1/A | Filing | Mar 16, 2023 | — |
| CORRESP | Letter to the SEC | Mar 15, 2023 | — |
| FWP | Free writing prospectus | Feb 27, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2023 | — |
| CORRESP | Letter to the SEC | Feb 21, 2023 | — |
| F-1/A | Filing | Feb 21, 2023 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2023 | — |
| F-1/A | Filing | Feb 1, 2023 | — |
| CORRESP | Letter to the SEC | Jan 31, 2023 | — |
| SEC STAFF LETTER | Filing | Nov 30, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2022 | — |
| CORRESP | Letter to the SEC | Nov 18, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Nov 18, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 19, 2022 | — |
| DRS/A | Filing | Sep 30, 2022 | — |
| DRSLTR | Filing | Jan 18, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 7, 2022 | — |
| DRS/A | Filing | Dec 20, 2021 | — |
| DRSLTR | Filing | Dec 17, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 2, 2021 | — |
| DRSLTR | Filing | Nov 19, 2021 | — |
| DRS/A | Filing | Nov 19, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 26, 2021 | — |
| DRS | Filing | Sep 28, 2021 | — |
Showing 132 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GDTC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Singapore
- Headquarters
- 1 Commonwealth Lane, Singapore
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1873093
- Former names
- CytoMed Therapeutics Pte. Ltd. (until Nov 30, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.